Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies News Story

$3.68 -0.1  -3.4%

Last Trade - 11/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £111.0m
Enterprise Value £80.5m
Revenue £n/a
Position in Universe 4724th / 6853

AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference

Wed 31st March, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210331:nGNXb2rsDY&default-theme=true


GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) --
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
company conducting human clinical trials of adeno-associated virus (AAV)-based
gene therapies for the treatment of rare diseases, today announced that
Company management will participate in the following virtual conferences:
* Wells Fargo Biotech Corporate Access Day (April 6, 2021)
Sue Washer, President & Chief Executive Officer, and Bill Sullivan, Chief
Financial Officer, will host investor one-on-one and small group meetings. For
more information, please contact your Wells Fargo representative.
* Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean
(April 6-9, 2021)
An AGTC corporate update by Ms. Washer and Mark Shearman, PhD, Chief
Scientific Officer, will be available for registered attendees to view
on-demand throughout the entirety of the conference. Please visit
www.meetingonthemed.com for full information including registration.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and constructing all
critical gene therapy elements and bringing them together to develop
customized therapies that address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on
the Company’s industry leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS disorders. In
recent years AGTC has entered into strategic partnerships with companies
including Otonomy, a biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology, and Bionic Sight, an innovator in the
emerging field of optogenetics and retinal coding.

IR/PR Contacts:
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com 

(https://www.globenewswire.com/NewsRoom/AttachmentNg/542616ce-01ae-469d-b4ff-5285f7e0584e)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.